HHU Stock Chart & Stats
€0.06
<€0.01(10.91%)
At close: 4:00 PM EDT
€0.06
<€0.01(10.91%)
Day’s Range― - ―
52-Week Range€0.05 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)14.35K
Market Cap
€436.59M
Enterprise Value€591.39
Total Cash (Recent Filing)€10.08M
Total Debt (Recent Filing)€26.75M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Sep 24, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,332,530,000
10 Day Avg. Volume8,961
30 Day Avg. Volume14,350
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€3.00M
Bulls Say, Bears Say
Bulls Say
Specialized Allergen Immunotherapy FocusA clear, specialized business model in AIT targets a durable clinical need (respiratory allergies) with established treatment pathways. Regulatory and clinical barriers to entry and recurring treatment regimens support steady long-term demand and defendable market positioning in Europe.
Integrated Development, Manufacturing And CommercializationVertical integration provides control over quality, supply continuity and regulatory compliance across product lifecycle. This reduces dependency on third-party manufacturers, aids regulatory submissions, and supports consistent product availability—advantages that sustain operations and margins over time.
Established AIT Portfolio (pollens And House Dust Mite)A diversified product set addressing common allergens spreads commercial risk across seasons and indications. Coupled with diagnostic products, this portfolio enables cross-selling and recurring prescriptions, creating a more resilient revenue base tied to persistent prevalence of allergic disease in core markets.
Bears Say
Declining Revenue And Deep Operating LossesSustained revenue decline and severe negative margins indicate difficulty converting product sales into profitable operations. Continued losses constrain reinvestment in R&D and commercialization, increase reliance on external financing, and undermine long-term competitiveness and strategic initiatives.
Negative Equity And High LeverageLiabilities exceeding assets and elevated leverage reduce financial flexibility, heighten refinancing and covenant risks, and limit the firm's ability to fund new product launches or acquisitions. This structural weakness can impede long-term strategy execution and market expansion.
Negative Operating And Free Cash FlowPersistent cash outflows from operations and sharply worsening free cash flow growth signal a cash burn profile. Without sustainable operating cash generation, the company will remain dependent on external capital, increasing dilution or debt risk and constraining long-term investment in growth.
Allergy Therapeutics News
HHU FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest stock price was €0.05 and its highest was €0.16 in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is €436.59M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Sep 24, 2026 which is in 55 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Mar 31, 2026. The company reported -€0.005 earnings per share for the quarter, the consensus estimate of -€0.005 by €0.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate is >-0.01.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,332,530,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -€0.005 in its last earnings report, expectations of -€0.005. Following the earnings report the stock price went down -2.679%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in DE:HHU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―